

# CARDIOGENIC SHOCK


## ECMO management in the ICU: status 2020

Prof. dr. Dirk Vlasselaers  
Prof. dr. Dieter Dauwe

Dienst Intensieve Geneeskunde  
UZ Leuven



# V-A ECMO



**E**  
Extremis

**Stage E “Extremis”.** A patient with circulatory collapse, frequently (but not always) in refractory cardiac arrest with ongoing cardiopulmonary resuscitation (CPR) or are being supported by multiple simultaneous acute interventions including ECMO-facilitated CPR. These are patients with multiple clinicians at bedside laboring to address multiple simultaneous issues related to the lack of clinical stability of the patient.

**D**  
Deteriorating

**Stage D “Deteriorating or Doom”.** A patient that is similar to category C but is getting worse. They have failure to respond to initial interventions.

**C**  
Classic

**Stage C “Classic” Cardiogenic Shock.** A patient that manifests with hypoperfusion that requires intervention (inotrope, pressor or mechanical support, ECMO) beyond volume resuscitation to restore perfusion. These patients typically present with relative hypotension.

**B**  
Beginning


**Stage B “Beginning” Cardiogenic Shock.** A patient who has clinical evidence of relative hypotension or tachycardia without hypoperfusion.

**A**  
At Risk

**Stage A “At Risk”.** A patient who is not currently experiencing signs or symptoms of cardiogenic shock, but is at risk for its development. These patients may include those with acute myocardial infarction, acute and/or acute on chronic heart failure symptoms.



# CENTRAL ILLUSTRATION: Definitions of SCAI Shock Stages A Through E, With Associated Cardiac Intensive Care Unit and Hospital Mortality in Each SCAI Shock Stage



Jentzer, J.C. et al. J Am Coll Cardiol. 2019;74(17):2117-28.

**V-A ECMO**

Biventricular support  
Oxygenation benefit  
*cave: afterload* ↑




# Cardiogenic shock & MCS: the challenge

- **GOAL** = restore end-organ perfusion asap
- pair the right patient with the right device at the right time
- **V-A ECMO**
  - biventricular support
    - ↓ preload
    - ↑ MAP
    - ↑ cardiac output (3-7 l/min)
  - pulmonary support
    - secures oxygenation
- **Impella CP/5.0**
  - LV support
    - ↓ preload
    - ↓ MAP
    - ↑ cardiac output (3-5 l/min)
  - no pulmonary support




# ECLS in cardiac arrest and cardiogenic shock


Cardiogenic shock **30-day survival**



# 30-day and 1 year survival in Impella CP/5.0 and ECMO supported AMI-patients: retrospective analysis



Number at risk		Days						
		0	5	10	15	20	25	30
Impella	90			47		41		40
ECMO	38			24		20		19



Number at risk		Months				
		0	3	6	9	12
Impella	90		37	32	31	29
ECMO	38		14	13	12	12

Karami et al. Eur Heart J Acute Cardiovasc Care 2020; 9(2):164-172



# V-A ECMO: advantages & risks

- Easy access / cannulation @ the **bedside**
    - percutaneous/surgical
  - **Biventricular** support
  - **Oxygenation** benefit: pulmonary support
    - ↓ ventilator-induced heart-lung interactions
  - inter-hospital **transport** in controlled conditions
  - **cave: LV-afterload ↑ & unloading LV :**
    - ↑ myocardial wall stress, pulmonary edema & risk intracardiac thrombosis
- ↑ organ perfusion & function



**Peripheral V-A ECMO = ↑ afterload for acutely dysfunctional left ventricle**

**↑ risk for LV distention**

**↓ LV unloading**

**↑ thrombo-embolic risk**

**cerebral & coronary embolism**

**pulmonary edema**

**↑ EDV & ↑ EDP**


**↓ coronary perfusion pressure**

**↓ myocardial recovery**



# V-A ECMO: management issues

- Early phase : inter-hospital **transport**
  - LV-unloading?!
    - pharmacologic venting
  - volume-status
    - bleeding ?
  - differential hypoxemia (watershed-zone)
    - Harlequin syndrome / North-South syndrome
    - ventilatory & flow management



# V-A ECMO: management issues

- Early phase in **ICU**
  - LV-unloading?!
    - pharmacologic and/or mechanical venting
  - differential hypoxemia (Harlequin syndrome / North-South syndrome)
  - vascular problems: limb ischemia; compartment syndrome
  - hemodynamic monitoring:
    - ABP(right), NIRS<sup>4</sup>, SaO<sub>2</sub>(right), SvO<sub>2</sub>, Swan-Ganz, TTE/TOE
  - bleeding ← **anticoagulation** → thrombosis:



# V-A ECMO: management issues

- **Weaning** phase
  - hemodynamic assessment: echocardiography !
  - strategies
    - pharmacologic support
    - ECMELLA-concept
    - ventilatory management
  - anticoagulation
  - bridge to ...







# VA-ECMO Management ICU

## CAPITA SELECTA



**HARLEQUIN**

Recognize  
Differential Hypoxemia



**UNLOADING**

Medical  
Management



**WEANING**

Medical  
Management




# VA-ECMO - Patient Interactions

**PARTIAL BYPASS**








**Hemodynamic Support  
Unloading (Right) Heart  
Unloading Pulmonary Circulation**

**Gas Exchange**



# Dynamic Flow Competition



CT

Aortogram Cathlab



# Recognize Differential Hypoxemia



## “CONDITIO SINE QUA NON”:


- Peripheral Fem-Fem VA-ECMO
- ‘RECOVERY’ HEART
- Respiratory Failure

## RECOGNIZE:


- ABG/POx right arm
- NIRS<sup>4</sup>

## MANAGE:

- Increase ventilatory support
- ECMO reconfiguration / mode switch
- ...



# Recognize Differential Hypoxemia



**PRESERVE**

## “CONDITIO SINE QUA NON”:

- Peripheral Fem-Fem VA-ECMO
- ‘RECOVERY’ HEART
- Respiratory Failure

## RECOGNIZE:


- ABG/POx right arm
- NIRS<sup>4</sup>

## MANAGE:


- Increase ventilatory support
- ECMO reconfiguration / mode switch
- ...




# “Medical” Unloading Strategies



Left Heart Inflow-Outflow Imbalance



# “Medical” Unloading Strategies



Restoring Left Heart  
Inflow-Outflow Balance

**CONSIDER TOTAL SYSTEMIC FLOW** ( $CO_{NTV} + CO_{ECMO}$ )

- Reduce '*SUPRAPHYSIOLOGIC*' ECMO-flow

**CARDIOPULMONARY INTERACTIONS**

- High PEEP strategy

**PHARMACOLOGICAL AFTERLOAD OPTIMIZATION**

- Optimize SVR

**PHARMACOLOGICAL 'VENTING'**

- MILD inotropic 'kick'

**+ INCREASE ANTICOAGULATION TARGETS**



# Weaning VA-ECMO



**TIMING IS CRUCIAL**

(Elective vs accelerated “push off”)



# Weaning VA-ECMO


## Incentives for an “Official Weaning Trial” - Assess q24h



Resolution of Shock

Resolution of Major  
Metabolic Disturbances

Augmentation > 24h




ETCO<sub>2</sub> ↑



Sustained Hemodynamics  
at Partial ECMO-support  
with ‘reasonable’ # pressors

Echocardio Contractility ↑



# Weaning VA-ECMO



**The heart is preload ‘starved’ during VA-ECMO support**  
(partial bypass)

“Crude” and “static” eyeballing during support  
contains limited prognostic information



More advanced and **DYNAMIC** assessment needed  
**LOAD DEPENDENT CONTRACTILE RESERVE**  
(Preload  $\uparrow$  and Afterload  $\downarrow$  Recruitability)  
“Official VA-ECMO Weaning Trial”



# Weaning VA-ECMO



## PREPARE:

Ensure optimal volume state  
Increase/initiate inotropic support  
Increase lung protective ventilation  
Ensure optimal anticoagulation



Gradual step-down ECMO blood flow  
**NEVER** switch of FGF





## MONITOR:

Hemodynamics  
Echocardiography  
Gas exchange  
Differential hypoxemia ?



**DECIDE**  
**HAVE A FAILURE PLAN**



# Weaning VA-ECMO



## PAUCITY OF DATA

Intensive Care Med (2011) 37:1738–1745  
DOI 10.1007/s00134-011-2358-2

ORIGINAL

Nadia Aissaoui  
Charles-Edouard Luyt  
Pascal Leprince  
Jean-Louis Trouillet  
Philippe Léger  
Alain Pavie  
Benoit Diebold  
Jean Chastre  
Alain Combes

**Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock**











# Weaning VA-ECMO



## DYNAMIC Echo Assessment

At 1-1.5 L/min ECMO blood flow:

- LVOT VTI  $\geq$  10-12 cm
- TDSa MV  $\geq$  6 cm/s
- LVEF  $\geq$  20-25%
- NO ventricular Interdependence



# Weaning VA-ECMO



## Levosimendan ?



Effects of Levosimendan on Endothelial Function and Hemodynamics During Weaning From Venous-Arterial Extracorporeal Life Support

Fabio Sangalli, MD,<sup>1</sup> Leonello Avalli, MD,<sup>2</sup> Matteo Laratta, MD,<sup>1,3</sup> Francesco Formica, MD,<sup>1,3</sup> Elena Maggioni, MD,<sup>4</sup> Rosa Caruso, CPT,<sup>1</sup> Maria Cristina Costa, CPT,<sup>1</sup> Marco Guazzi, MD, PhD,<sup>1</sup> and Roberto Fumagalli, MD, PhD<sup>1,3</sup>

Review

Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: systematic review and meta-analysis

Lucrecia Maria Burgos,<sup>1</sup> Leonardo Seoane,<sup>2</sup> Juan Francisco Furmento,<sup>3</sup> Juan Pablo Costabel,<sup>2</sup> Mirta Diez,<sup>4</sup> Mariano Vrancic,<sup>5</sup> Nadia Aissaoui,<sup>6</sup> Mariano Noel Benzon<sup>7</sup> and Daniel Navia<sup>8</sup>

Vally et al. *Ann Intensive Care* (2019) 9:24  
https://doi.org/10.1186/s13054-019-0505-1

Annals of Intensive Care

ASAIO Journal 2013

Adult Circulatory Support

RESEARCH Open Access

Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit

Shamir Vally<sup>1</sup>, Cyril Fendynus<sup>1,2</sup>, Romain Persichini<sup>1</sup>, Bruno Bouchet<sup>1</sup>, Eric Braunberger<sup>1</sup>, Hugo Lo Pinto<sup>1</sup>, Olivier Martinet<sup>1</sup>, David Vandroux<sup>1</sup>, Thomas Aujoulat<sup>1</sup>, Jérôme Ailyn<sup>1</sup> and Nicolas Allou<sup>1,3\*</sup>

Guilherme et al. *Critical Care* (2020) 24:442  
https://doi.org/10.1186/s13054-020-03122-y

Critical Care

RESEARCH Open Access

Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

Enrique Guilherme<sup>1</sup>, Matthias Jacquet-Lagréze<sup>2\*</sup>, Matteo Pozzi<sup>3</sup>, Felix Achana<sup>4</sup>, Xavier Armoyn<sup>5\*</sup> and Jean-Luc Fellahi<sup>6\*</sup>

Levosimendan May Improve Weaning Outcomes in Venous-Arterial ECMO Patients

Alessandro Afroniti, Isidoro Di Bella, Davide Carino, and Tomislav Ragnj

British Journal of Anaesthesia, 117 (1): 52-8 (2016)

doi: 10.1093/bja/aeu151  
Cardiovascular

BJA

Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery

K. Distelmaier<sup>1</sup>, C. Roth<sup>1</sup>, L. Schrutka<sup>1</sup>, C. Binder<sup>1</sup>, B. Steinlechner<sup>2</sup>, G. Heinz<sup>1</sup>, I. M. Lang<sup>1</sup>, G. Maurer<sup>1</sup>, H. Koinig<sup>3</sup>, A. Niessner<sup>1</sup>, M. Hülsmann<sup>1</sup>, W. Speidl<sup>1</sup> and G. Gollasch<sup>1\*</sup>

## CONFLICTING LOW QUALITY EVIDENCE



HOWEVER

- Majority positive
- Pharmacodynamics/kinetics
- Non-ECLS data

LOW THRESHOLD

- Consider early
- Especially: cardiac surgery,  $\beta$ -blockers, arrhythmias, ...



# VA-ECMO Management ICU

## CAPITA SELECTA



### HARLEQUIN

Understand Pathophysiology  
And Recognize  
Differential Hypoxemia



### UNLOADING

Fully Exploit  
“Medical” Options



### WEANING

Expert  
Multimodal  
Assessment  
Timing is Crucial



